Shuttle Pharmaceuticals Files 8-K, Faces Listing Concerns
Ticker: SHPH · Form: 8-K · Filed: Mar 13, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: material-agreement, delisting-risk, regulatory-filing
TL;DR
Shuttle Pharma's 8-K flags a material agreement AND potential delisting – big trouble ahead.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on March 13, 2025, reporting a material definitive agreement and a notice of delisting or failure to satisfy continued listing rules. The filing indicates potential issues with the company's listing status.
Why It Matters
This filing signals potential significant challenges for Shuttle Pharmaceuticals, including the risk of delisting, which could severely impact its stock and operations.
Risk Assessment
Risk Level: high — The company has received a notice of delisting or failure to satisfy continued listing rules, indicating a high risk of its securities being removed from the exchange.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- March 12, 2025 (date) — Earliest event reported
- March 13, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-41488 (identifier) — SEC File Number
- 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (address) — Principal executive offices
- (240) 430-4212 (phone_number) — Business phone
FAQ
What is the nature of the material definitive agreement entered into by Shuttle Pharmaceuticals?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What specific listing rule or standard has Shuttle Pharmaceuticals failed to satisfy?
The filing states 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not detail the specific rule or standard.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated March 12, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
What is the SEC file number for Shuttle Pharmaceuticals Holdings, Inc.?
The SEC file number for Shuttle Pharmaceuticals Holdings, Inc. is 001-41488.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 13, 2025 regarding Shuttle Pharmaceuticals Holdings, Inc. (SHPH).